Inaphaea
Private Company
Total funding raised: $1.2M
Overview
Inaphaea Biolabs is a UK-based translational CRO founded in 2021, offering specialized cell-based assay services in oncology and women's health to pharmaceutical partners. The company differentiates itself through a collaborative, scientist-to-scientist service model and an integrated network of partners providing complementary capabilities in biological modelling, formulation, enzyme assays, AI toxicity prediction, and tissue analysis. As a subsidiary of ValiRx, it is positioned as a service provider supporting external drug discovery pipelines rather than developing its own therapeutic assets.
Technology Platform
Specialized cell-based assay development for oncology and women's health, supported by an integrated network of partners offering biological modelling, formulation, enzyme assays, AI toxicity prediction, liver models, and tissue analysis.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Inaphaea competes with large, full-service CROs (e.g., Labcorp, Charles River) and numerous specialized boutique assay providers. Its differentiation lies in its focused therapeutic expertise, collaborative service model, and unique ability to bundle core cell assays with advanced partner services like AI toxicity prediction and digital pathology through a single point of contact.